Prelude Therapeutics stockholders elect two Class I directors, ratify EY as auditor

Prelude Therapeutics Inc

Paul A. Friedman, M.D. elected as Class I director with 31,165,370 votes for, 1,762,716 withheld.
David P. Bonita, M.D. elected as Class I director with 31,007,172 votes for, 1,920,914 withheld.
Ratification of Ernst & Young LLP as independent auditor for FY2024: 34,994,229 for, 57,512 against, 14,440 abstaining.
Broker non-votes of 2,138,095 on director elections; none on auditor ratification.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.